AI-Based Predictions of Molecular Target Activity from Blind Chemical Structures

IRVINE, Calif., June 25, 2024 — GATC Health Corp, a technology company advancing drug discovery and disease prediction using artificial intelligence (AI), announces that The American Journal of Biomedical Science & Research has published a paper entitled “AI-Based Predictions of Molecular Target Activity from Blind Chemical Structures,” co-authored by GATC’s Ian Jenkins, Vaishnavi Narayan, Jayson Uffens, Eric J. Mathur, Saman Mirzaei, Krista Casazza, and Jonathan RT Lakey. 

The paper discusses the results of a blind challenge that demonstrated GATC Health’s AI platform’s ability to accurately predict protein-small molecule interactions, establishing a standardized benchmark against which all other AI platforms can be compared. 

These molecular interactions, which are the cornerstone of modern drug development, have enabled elucidation of the underlying biological processes, resulting in effective in silico therapeutic design. As the primary functional molecules in cells, proteins play critical roles in virtually all biological activities, from catalyzing metabolic reactions to transmitting signals within and between cells. Understanding how proteins interact with exogenous molecules, including small drug-like compounds, is essential for elucidating function and rational design of new drugs and employment of a rational poly-pharmaceutical approach. 

GATC will continue to write and publish scientific insights as part of our work to transform drug discovery and improve human health. We also welcome inquiries and dialogue about this vital work. 

About GATC Health

GATC Health Corp is a technology company revolutionizing disease prediction and drug discovery and development through its transformative AI platform and approach, which de-risks drug pipelines and accelerates new therapies to treat disease with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC Health envisions the future of medicine now, where health is protected, disease is reversed, and every person’s unique biology is treated with precision.